SAN DIEGO , Aug. 20, 2024 /PRNewswire/ -- Neomorph, Inc., today announced the appointment of Dr.
Peter Lebowitz to its Board of Directors. Dr. Lebowitz has deep experience in oncology drug discovery and clinical development and has facilitated the approval of 15 novel drugs over his career.
"We are excited to welcome Peter to our Board of Directors. Peter's broad experience in oncology complements Neomorph's efforts in this core therapeutic area," said Philip Chamberlain , D.Phil.
, co-founder, President, and Chief Executive Officer of Neomorph. "His expertise will benefit Neomorph tremendously as our pipeline of novel glues advances into the clinic." "Peter is a welcome addition to the Neomorph board with significant experience in both clinical development and patient care, and we look forward to working together," said Cam Wheeler , Partner at Deerfield Management and Chair of Neomorph's Board of Directors.
"The Neomorph team has already taken major steps toward creating a potential best-in-industry molecular glue platform," said Dr. Lebowitz. "Using this platform, the team is now rapidly advancing a variety of innovative and differentiated programs to the clinic.
" Dr. Lebowitz currently serves as the CEO of Third Arc Bio. Prior to Third Arc, he was the Global Head of Oncology R&D for Johnson & Johnson, where he built a world-class, end-to-end J&J oncology team that delivered 13 new oncology drugs by leveraging both internal R&D excellence and external partnerships.
Dr. Lebo.